Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Hryz Biotech Co. has 2 pending office actions active in the Biotechnology & Pharmaceuticals technology area. Despite the multiple actions, prosecution is concentrated under 1 distinct examiner and 1 distinct art unit. This indicates a highly centralized review process where all active matters are handled by the same authority.
MARVICH, MARIA is identified as the busiest examiner, with 2 pending office actions. This figure matches the total of 2 pending office actions for the portfolio, showing that this examiner is responsible for all current prosecution tasks reported for the company.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARVICH, MARIA | 2 | 54.9% | +28.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17843912 | METHODS OF OBTAINING TUMOR-SPECIFIC T CELL RECEPTORS | MARVICH, MARIA | 46d overdue |
| 17843917 | METHODS OF OBTAINING TUMOR-SPECIFIC T CELL RECEPTORS | MARVICH, MARIA | 18d overdue |
| Art Unit | Apps |
|---|---|
| 1634 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17843917 | METHODS OF OBTAINING TUMOR-SPECIFIC T CELL RECEPTORS | MARVICH, MARIA | 1634 | §112Other | Final Rejection | 18d overdue | Pending | Jun 17, 2022 |
| 17843912 | METHODS OF OBTAINING TUMOR-SPECIFIC T CELL RECEPTORS | MARVICH, MARIA | 1634 | §112DP | Final Rejection | 46d overdue | Pending | Jun 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial